Optimal Utilization of Ki67 Testing in HR-Positive/HER2-Negative Early Breast Cancer: Education and Resources for the Oncology and Pathology Healthcare Teams

Learn more about Ki67 testing and learn how to accurately interprete and apply the test results for the optimal selection of therapy for patients with HR-positive HER2-negative early breast cancer.

Share

Program Content

Activities

Ki-67 Testing in EBC
What I Want My Colleagues to Know About Ki67 in HR-Positive/HER2-Negative Early Breast Cancer
Clinical Thought
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: December 28, 2021

Expires: December 27, 2022

View Activity
Ki-67 Use in HR+ EBC
Latest Insights on Ki-67 Use in HR-Positive/HER2-Negative Early Breast Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: September 26, 2022

Expires: September 25, 2023

View Activity

Activities

EBC: Utility of Ki67 Testing
Optimal Utilization of Ki67 Testing in HR-Positive/HER2-Negative Early Breast Cancer: Education and Resources for the Oncology and Pathology Healthcare Teams
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 04, 2022

Expires: March 03, 2023

View Activity

Activities

EBC: Utility of Ki67 Testing
Optimal Utilization of Ki67 Testing in HR-Positive/HER2-Negative Early Breast Cancer: Education and Resources for the Oncology and Pathology Healthcare Teams
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: May 11, 2022

Expires: May 10, 2023

View Activity

Faculty

cover img faculity

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Sunil Badve, MD, FRCPath

cover img faculity

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Cancer Center
Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Supporters

This activity is supported by an educational grant from

Lilly